150 related articles for article (PubMed ID: 11060691)
1. Soluble cytokine receptors: novel immunotherapeutic agents.
Fernandez-Botran R
Expert Opin Investig Drugs; 2000 Mar; 9(3):497-514. PubMed ID: 11060691
[TBL] [Abstract][Full Text] [Related]
2. Soluble cytokine receptors: basic immunology and clinical applications.
Fernandez-Botran R
Crit Rev Clin Lab Sci; 1999 Jun; 36(3):165-224. PubMed ID: 10407682
[TBL] [Abstract][Full Text] [Related]
3. Soluble cytokine receptors in biological therapy.
Fernandez-Botran R; Crespo FA; Sun X
Expert Opin Biol Ther; 2002 Aug; 2(6):585-605. PubMed ID: 12171504
[TBL] [Abstract][Full Text] [Related]
4. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
5. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor alpha, and interleukin-6 levels in rheumatoid arthritis. Longitudinal evaluation during methotrexate and azathioprine therapy.
Barrera P; Boerbooms AM; Janssen EM; Sauerwein RW; Gallati H; Mulder J; de Boo T; Demacker PN; van de Putte LB; van der Meer JW
Arthritis Rheum; 1993 Aug; 36(8):1070-9. PubMed ID: 8393676
[TBL] [Abstract][Full Text] [Related]
6. Tumor necrosis factor (TNF)-alpha-induced interleukin-8 in human blood cultures discriminates neutralization by the p55 and p75 TNF soluble receptors.
Frishman JI; Edwards CK; Sonnenberg MG; Kohno T; Cohen AM; Dinarello CA
J Infect Dis; 2000 Dec; 182(6):1722-30. PubMed ID: 11069245
[TBL] [Abstract][Full Text] [Related]
7. Etanercept: therapeutic use in patients with rheumatoid arthritis.
Garrison L; McDonnell ND
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I65-9. PubMed ID: 10577976
[TBL] [Abstract][Full Text] [Related]
8. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Feldmann M; Maini RN
Annu Rev Immunol; 2001; 19():163-96. PubMed ID: 11244034
[TBL] [Abstract][Full Text] [Related]
9. Interleukin 1 (IL-1) receptor antagonist, soluble tumor necrosis factor receptors, IL-1 beta, and IL-8--markers of remission in rheumatoid arthritis during treatment with methotrexate.
Seitz M; Loetscher P; Dewald B; Towbin H; Rordorf C; Gallati H; Gerber NJ
J Rheumatol; 1996 Sep; 23(9):1512-6. PubMed ID: 8877917
[TBL] [Abstract][Full Text] [Related]
10. PEG-sTNF-RI. Amgen.
Darlington C
Curr Opin Investig Drugs; 2003 May; 4(5):583-7. PubMed ID: 12833653
[TBL] [Abstract][Full Text] [Related]
11. PEGylated recombinant human soluble tumour necrosis factor receptor type I (r-Hu-sTNF-RI): novel high affinity TNF receptor designed for chronic inflammatory diseases.
Edwards CK
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I73-81. PubMed ID: 10577978
[TBL] [Abstract][Full Text] [Related]
12. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes.
Seitz M; Zwicker M; Loetscher P
Arthritis Rheum; 1998 Nov; 41(11):2032-8. PubMed ID: 9811059
[TBL] [Abstract][Full Text] [Related]
13. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis.
Goldenberg MM
Clin Ther; 1999 Jan; 21(1):75-87; discussion 1-2. PubMed ID: 10090426
[TBL] [Abstract][Full Text] [Related]
14. The role of cytokines in rheumatoid arthritis: inhibition of cytokines in therapeutic trials.
Moreland LW
Drugs Today (Barc); 1999; 35(4-5):309-19. PubMed ID: 12973435
[TBL] [Abstract][Full Text] [Related]
15. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.
Robak T; Gladalska A; Stepień H
Eur Cytokine Netw; 1998 Jun; 9(2):145-54. PubMed ID: 9681390
[TBL] [Abstract][Full Text] [Related]
16. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies.
Ribbens C; André B; Kaye O; Kaiser MJ; Bonnet V; de Groote D; Franchimont N; Malaise MG
Eur Cytokine Netw; 2000 Dec; 11(4):669-76. PubMed ID: 11125312
[TBL] [Abstract][Full Text] [Related]
17. Immune complexes from rheumatoid arthritis synovial fluid induce FcgammaRIIa dependent and rheumatoid factor correlated production of tumour necrosis factor-alpha by peripheral blood mononuclear cells.
Mathsson L; Lampa J; Mullazehi M; Rönnelid J
Arthritis Res Ther; 2006; 8(3):R64. PubMed ID: 16569263
[TBL] [Abstract][Full Text] [Related]
18. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
Moreland LW; Baumgartner SW; Schiff MH; Tindall EA; Fleischmann RM; Weaver AL; Ettlinger RE; Cohen S; Koopman WJ; Mohler K; Widmer MB; Blosch CM
N Engl J Med; 1997 Jul; 337(3):141-7. PubMed ID: 9219699
[TBL] [Abstract][Full Text] [Related]
19. In vitro comparison of inhibiting ability of soluble TNF receptor p75 (TBP II) vs. soluble TNF receptor p55 (TBP I) against TNF-alpha and TNF-beta.
Terlizzese M; Simoni P; Antonetti F
J Interferon Cytokine Res; 1996 Dec; 16(12):1047-53. PubMed ID: 8974008
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis.
Murray KM; Dahl SL
Ann Pharmacother; 1997 Nov; 31(11):1335-8. PubMed ID: 9391689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
